IAVI and NineSigma Collaborate on New Approaches to AIDS Vaccine
Source: The Wall Street Journal
A collaboration between NineSigma and the International AIDS Vaccine Initiative (IAVI) is helping to advance HIV vaccine research by identifying new approaches to the design of a potential vaccine. A leading worldwide provider of innovation services, NineSigma has connected IAVI with some of the world's leading biomedical researchers, and helped it identify two scientists who will receive a total of $875,000 to develop solutions for generating stable protein complexes for use in AIDS vaccines. The grants were issued by the Innovation Fund, a program of IAVI, which seeks out and underwrites the application ofnovel technologies to HIV vaccine design.